SCM
ARQT icon

Soleus Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Soleus Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-225,000
Closed -$2.23M – 95
2024
Q1 		$2.23M Buy
+225,000
New +$1.68M 0.17% 77

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Soleus Capital Management's ARQT Position: Q2 2024 in Review

Soleus Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2024, closing a stake of 225,000 shares — an estimated $2.23M sold.

Soleus Capital Management first reported a position in ARQT in Q1 2024 and held it in 1 quarter. The position peaked at $2.23M in Q1 2024. 186 funds tracked by Wall St. Rank hold ARQT as of Q2 2024.

  • Soleus Capital Management reported no remaining Arcutis Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Soleus Capital Management sold 225,000 Arcutis Biotherapeutics shares in Q2 2024, an estimated $2.23M.
  • Soleus Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2024 and held it in 1 quarter.
  • Soleus Capital Management's Arcutis Biotherapeutics position peaked at $2.23M in Q1 2024.
  • 186 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2024.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.